Wu Fei-Fan, Hung Yen-Chu, Tsai Y H, Yang Jen-Tsung, Lee Tsong-Hai, Liow Chia-Wei, Lee Jiann-Der, Lin Chung-Jen, Peng Tsung-I, Lin Leng-Chieh
Department of Emergency Medicine, Chang Gung Memorial Hospital, No. 6, W. Sec., Jiapu Rd., Puzih City, Chiayi County, 613, Taiwan, ROC.
Department of Neurology, Chang Gung University, Taoyuan, Taiwan.
BMC Cardiovasc Disord. 2017 Jun 13;17(1):154. doi: 10.1186/s12872-017-0590-6.
Many studies have determined that dehydration is an independent predictor of outcome after ischemic stroke (IS); however, none have determined if the use of thrombolytic therapy modifies the negative impact of poor hydration. To inform the stroke registry established at our institution, we conducted a retrospective study to determine if dehydration remains a negative prognostic factor after IS patients treated with tissue plasminogen activator (tPA).
Between 2007 and 2012, we recruited 382 subjects; 346 had data available and were divided into 2 groups on the basis of their blood urea nitrogen/creatinine (BUN/Cr) ratio. Dehydrated subjects had a BUN/Cr ratio ≥ 15; hydrated subjects had a BUN/Cr < 15. The primary outcome was impairment at discharge as graded by the Barthel Index (BI) and the modified Rankin Scale (mRS).
The dehydration group had a greater mean age; more women; lower mean levels of hemoglobin, triglycerides, and sodium; and higher mean potassium and glucose levels. A favorable outcome as assessed by the mRS (≤2) was significantly less frequent among dehydrated subjects, but a favorable outcome by the BI (≥60) was not. Logistic regression and multivariate models confirmed that dehydration is an independent predictor of poor outcome by both the mRS and the BI; however, it was not predictive when patients were stratified by Trial of Org 10,172 in Acute Stroke Treatment subtype.
Our findings indicate that use of thrombolytic therapy does not eliminate the need to closely monitor hydration status in patients with IS.
许多研究已确定脱水是缺血性卒中(IS)后预后的独立预测因素;然而,尚无研究确定溶栓治疗的使用是否能改变水化状态不良的负面影响。为了给我们机构建立的卒中登记处提供信息,我们进行了一项回顾性研究,以确定在接受组织型纤溶酶原激活剂(tPA)治疗的IS患者中,脱水是否仍然是一个负面的预后因素。
2007年至2012年期间,我们招募了382名受试者;346名有可用数据,并根据其血尿素氮/肌酐(BUN/Cr)比值分为两组。脱水受试者的BUN/Cr比值≥15;水化正常受试者的BUN/Cr<15。主要结局是出院时由巴氏指数(BI)和改良Rankin量表(mRS)分级的功能障碍。
脱水组的平均年龄更大;女性更多;血红蛋白、甘油三酯和钠的平均水平更低;钾和葡萄糖的平均水平更高。根据mRS评估(≤2),脱水受试者中获得良好结局的频率显著更低,但根据BI评估(≥60)则并非如此。逻辑回归和多变量模型证实,脱水是mRS和BI评估不良结局的独立预测因素;然而,当根据急性卒中治疗中组织纤溶酶原激活剂(tPA)的10,172项试验对患者进行分层时,脱水并无预测作用。
我们的研究结果表明,溶栓治疗的使用并不能消除对IS患者水化状态进行密切监测的必要性。